Secukinumab Approved for Plaque Psoriasis in Children, Adolescents

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.